Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Lynne V. Abruzzo, Barbara L. Andersen, Farrukh T. Awan, Seema A. Bhat, Allison Dean, Margaret Lucas, Christin Banks, Cara Grantier, Nyla A. Heerema, Gerard Lozanski, Kami J. Maddocks, Thomas R. Valentine, David M. Weiss, Jeffrey A. Jones, Jennifer A. Woyach, John C. Byrd

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Sort by
Weight
Alphabetically

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

Fingerprint

Medicine & Life Sciences